While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
Our bodies are capable of creating a lot of odd odors: from bad breath to gross gas, stinky sweat, and even strange-smelling sneezes. Now, you can add foul-smelling pimple pus to the list. Yep, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback